MINI REVIEW article
Front. Psychiatry
Sec. Psychopharmacology
This article is part of the Research TopicBridging the Gap: An Interdisciplinary Perspective on Ketamine in Psychiatric Disorders - Volume IIIView all 9 articles
Ketamine as an NMDA-Modulating Therapy in Bipolar Disorder: Rationale and Evidence
Provisionally accepted
- Medical University of Graz, Graz, Austria
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharmacotherapies often provide delayed or incomplete relief and may increase the risk of treatment-emergent affective switching. Recent evidence highlights the therapeutic potential of NMDA receptor antagonists, particularly ketamine and its S-enantiomer esketamine, as rapid-acting antidepressants. Methods: This narrative review synthesizes findings from randomized controlled trials, systematic reviews, and real-world studies investigating ketamine and esketamine in treatment-resistant bipolar depression. Emphasis was placed on antidepressant efficacy, safety, and the risk of mood destabilization. Results: Across multiple trials, ketamine produced rapid and robust antidepressant effects, with significant improvement in depressive symptoms within hours of administration. Data confirmed high response rates in treatment-resistant bipolar depression, while rapid-onset benefits with minimal switch risk. Further there is evidence on comparable efficacy and safety of intranasal esketamine in bipolar and unipolar depression, with no cases of mania or hypomania. Conclusions: Ketamine and esketamine represent mechanistically novel and clinically effective treatments for bipolar depression. Their rapid antidepressant action and low switch liability distinguish them from traditional antidepressants. Esketamine, with its favourable tolerability and intranasal administration, offers a promising adjunctive option for treatment-resistant bipolar depression. Long-term data are warranted to optimize maintenance strategies and confirm sustained safety and efficacy.
Keywords: Bipolar depression, Esketamine, Ketamine, NMDA - receptor, treatment resistant depression (TRD)
Received: 29 Dec 2025; Accepted: 12 Jan 2026.
Copyright: © 2026 Queissner, Fellendorf and Reininghaus. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Robert Queissner
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.